Clinical trials
Phase 2 Leukemia, Mast-Cell trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fred Hutchinson Cancer Center | 3 |
| Jason Robert Gotlib | 3 |
| Blueprint Medicines Corporation | 1 |
| Cogent Biosciences, Inc. | 1 |
| M.D. Anderson Cancer Center | 1 |
| Mayo Clinic | 1 |
| National Cancer Institute (NCI) | 1 |
| Novartis Pharmaceuticals | 1 |
| Stanford University | 1 |
| Wake Forest University Health Sciences | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Mast-Cell | 14 |
| Mastocytosis, Systemic | 7 |
| Leukemia, Biphenotypic, Acute | 6 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 |
| Burkitt Lymphoma | 5 |
| Leukemia, Myeloid, Acute | 5 |
| Leukemia | 4 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
| Lymphoma, Mantle-Cell | 4 |
| Myeloproliferative Disorders | 4 |
Trials
Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.